Cartesian Therapeutics, Inc.

Cartesian Therapeutics, Inc.verified

RNAC

Price:

$6.9

Market Cap:

$179.42M

Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in Phase I clinical trial to enhance the treatment of methylmalonic acidemia. It is also developing biologic therapies, such as SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout; and product candidates to treat IgA-mediated diseases, including IgA nephropathy, linear IgA bullous dermatitis, IgA pemphigus, and Henoch-Schonlein purpura. In addition, the company is developing gene therap...[Read more]

Industry

Biotechnology

IPO Date

2016-06-22

Stock Exchange

NASDAQ

Ticker

RNAC

The PE Ratio as of December 2025 (TTM) for Cartesian Therapeutics, Inc. (RNAC) is -5.19

According to Cartesian Therapeutics, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -5.19. This represents a change of 51.14% compared to the average of -3.43 of the last 4 quarters.

Cartesian Therapeutics, Inc. (RNAC) Historical PE Ratio (quarterly & annually)

How has RNAC PE Ratio performed in the past?

The mean historical PE Ratio of Cartesian Therapeutics, Inc. over the last ten years is -3.35. The current -5.19 PE Ratio has changed 15.41% with respect to the historical average. Over the past ten years (40 quarters), RNAC's PE Ratio was at its highest in in the June 2021 quarter at 21.66. The PE Ratio was at its lowest in in the December 2024 quarter at -11.31.

Quarterly (TTM)
Annual

Average

-3.35

Median

-3.13

Minimum

-12.09

Maximum

3.85

Cartesian Therapeutics, Inc. (RNAC) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Cartesian Therapeutics, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 1.20%

Maximum Annual PE Ratio = 3.85

Minimum Annual Increase = -131.87%

Minimum Annual PE Ratio = -12.09

Quarterly (TTM)
Annual
YearPE RatioChange
2024-5.991.20%
2023-0.46-112.01%
20223.85-131.87%
2021-12.09225.91%
2020-3.71127.32%
2019-1.63114.86%
2018-0.76-70.28%
2017-2.56-38.28%
2016-4.14-30.55%
2015-5.96-48.84%

Cartesian Therapeutics, Inc. (RNAC) Average PE Ratio

How has RNAC PE Ratio performed in the past?

The current PE Ratio of Cartesian Therapeutics, Inc. (RNAC) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

3-year avg

-0.87

5-year avg

-3.68

10-year avg

-3.35

Cartesian Therapeutics, Inc. (RNAC) PE Ratio vs. Peers

How is RNAC’s PE Ratio compared to its peers?

Cartesian Therapeutics, Inc.’s PE Ratio is greater than Eupraxia Pharmaceuticals Inc. (-6.44), less than Inventiva S.A. (-1.22), less than Nautilus Biotechnology, Inc. (-4.16), less than Orchestra BioMed Holdings, Inc. (-2.58), greater than MediWound Ltd. (-6.90), greater than Aardvark Therapeutics, Inc. Common Stock (-5.52), greater than Fennec Pharmaceuticals Inc. (-31.26), less than Avalo Therapeutics, Inc. (-2.52), less than NEONC TECHNOLOGIES HOLDINGS, INC. (-3.29), greater than Genfit S.A. (-5.72),

Build a custom stock screener for Cartesian Therapeutics, Inc. (RNAC) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Cartesian Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Cartesian Therapeutics, Inc. (RNAC) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Cartesian Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the PE Ratio?

How can you use the PE Ratio?

What is Cartesian Therapeutics, Inc.'s PE Ratio?

How is the PE Ratio calculated for Cartesian Therapeutics, Inc. (RNAC)?

What is the highest PE Ratio for Cartesian Therapeutics, Inc. (RNAC)?

What is the 3-year average PE Ratio for Cartesian Therapeutics, Inc. (RNAC)?

What is the 5-year average PE Ratio for Cartesian Therapeutics, Inc. (RNAC)?

How does the current PE Ratio for Cartesian Therapeutics, Inc. (RNAC) compare to its historical average?